Romidepsin for T-Cell Lymphoma
Name of the Trial
Why This Trial Is Important
"Because of the promising responses we've seen in the first cohort of this study, we've opened a new cohort specifically for patients with cutaneous T-cell lymphoma who have had two or fewer prior chemotherapy regimens," said Dr. Piekarz.
With this trial, researchers are seeking to determine whether romidepsin (FR901228, depsipeptide), a histone deacetylase inhibitor, can help bring about remission in patients with T-cell lymphoma.
"This trial is very exciting because it involves a new class of anticancer drugs that can change the way cells grow," said Dr. Bates. "Whereas many chemotherapy drugs work by causing damage to cells, histone deacetylase inhibitors like romidepsin turn on genes in cancer cells that inhibit cell growth and eventually cause the cancer cells to die."
"We are continuing to see a complete or partial response rate between 30 and 40 percent for patients with cutaneous T-cell lymphoma," Dr. Piekarz said. "And the response rate for patients with peripheral T-cell lymphoma has remained steady at 25 percent."
Who Can Join This Trial
Study Sites and Contact Information
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.